Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockade in heart failure: selective versus nonselective agents.

M Metra1, S Nodari, L Dei Cas

  • 1Department of Cardiology, University of Brescia, Brescia, Italy. metramarco@libero.it

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed
Summary

Long-term beta-blocker therapy benefits chronic heart failure patients. Different beta-blockers like carvedilol and metoprolol have unique properties affecting outcomes, with ongoing trials comparing their long-term prognostic impact.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Presence of viral spike protein and vaccinal spike protein in the blood serum of patients with long-COVID syndrome.

European review for medical and pharmacological sciences·2024
Same author

Serum proteomic profiling reveals potential inflammatory biomarkers in long-COVID patients: a comparative analysis with healthy controls.

European review for medical and pharmacological sciences·2023
Same author

Presence of viral spike protein and vaccinal spike protein in the blood serum of patients with long-COVID syndrome.

European review for medical and pharmacological sciences·2023
Same author

Linking pathogenic and likely pathogenic gene variants to long-COVID symptoms.

European review for medical and pharmacological sciences·2023
Same author

Autoantibodies in patients with post-COVID syndrome: a possible link with severity?

European review for medical and pharmacological sciences·2023
Same author

The Role of Olive Tree Polyphenols in the Prevention of COVID-19: A Scoping Review, part 1.

La Clinica terapeutica·2023

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Long-term beta-adrenoceptor antagonist (beta-blocker) therapy is proven beneficial for chronic heart failure.
  • The specific benefits of different beta-blockers, whether a class effect or agent-specific, remain unclear.
  • Metoprolol, bisoprolol, and carvedilol show prognostic benefits but possess distinct pharmacologic profiles.

Purpose of the Study:

  • To compare the long-term effects and prognostic impact of different beta-blockers in chronic heart failure.
  • To investigate whether the differing pharmacologic characteristics of beta-blockers influence long-term outcomes.
  • To evaluate the comprehensive blockade of cardiac adrenergic drive by carvedilol versus selective beta-blockers.

Main Methods:

  • Analysis of controlled clinical trials involving over 13,000 patients.

Related Experiment Videos

  • Comparison of pharmacologic characteristics: selective beta(1)-blockers (metoprolol, bisoprolol) versus carvedilol (beta(1), beta(2), alpha(1) blockade).
  • Ongoing comparison in the Carvedilol or Metoprolol European Trial (COMET) with over 3,000 randomized patients.

    • Main Results:

    • Selective beta-blockers cause varied acute hemodynamic responses, including reduced cardiac output.
    • Carvedilol shows no change in cardiac output and slight decrease in pulmonary pressures, with different initial adverse effects.
    • Carvedilol may offer more comprehensive adrenergic blockade, potentially increasing left ventricular function.

    Conclusions:

    • Differences in beta-blocker pharmacology may influence acute hemodynamic responses and initial adverse effects.
    • It remains controversial whether these pharmacological differences translate to significant variations in long-term therapy effects and patient outcomes.
    • Ongoing trials like COMET are crucial for determining the comparative long-term prognostic value of different beta-blockers in heart failure.